Abstract: This invention features the use of the spirolaxine of formula (I) for the treatment of those pathologies responding to the activation of the PPAR&ggr; receptor, such as the Type 2 insulin-resistant diabetes. This invention also features a pharmaceutical composition in which the spirolaxine of formula (I) acts as active principle in association with the all-trans retinoic acid of formula (II) for the treatment of those pathologies responding to the activation of the PPAR&ggr; receptor, such as the acute malignant haemopathies.
Abstract: Acne-affected skin has been found to be accompanied by the presence of matrix-degrading enzymes such as MMPs and neutrophil elastase, induction of neutrophils, and a reduction in procollagen biosynthesis. This invention treats scarring and inflammation accompanying acne by administering, topically or systemically, at least one of (i) an inhibitor of the matrix degrading enzymes and (ii) a cytokine inhibitor that alleviates inflammation and thus also alleviate neutrophil infiltration. Alleviating the matrix degradation and renormalizing procollagen biosynthesis allows for reduced inflammation and better natural repair of acne-affected skin. Inhibiting cytokines alleviates induction of MMPs in resident skin cells, and also alleviates inflammation with its concommitant induction of neutrophils from the blood stream bringing MMPs and elastase into the acne lesion.
Type:
Application
Filed:
May 9, 2001
Publication date:
November 25, 2004
Inventors:
John J. Voorhees, Sewon Kang, Gary J. Fisher
Abstract: The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of an integrin antagonist and an antineoplastic agent.
Type:
Application
Filed:
June 10, 2004
Publication date:
November 25, 2004
Inventors:
John P. McKearn, Gary Gordon, James J. Cunningham, Stephen T. Gately, Alane T. Koki, Jaime L. Masferrer
Abstract: A process for the production of 9-(Z)-retinoic acid is described which comprises reacting an alkali metal salt of 3-methyl-4-oxocrotonic acid with a C15-triphenyl-phosphonium salt. 9-(Z)-retinoic acid is used in the treatment of dermatological diseases.
Abstract: The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering an SSRI or analog or metabolite thereof and, optionally, a corticosteroid or other compound to the patient. The invention also features a pharmaceutical composition containing an SSRI or analog or metabolite thereof and a corticosteroid or other compound for the treatment or prevention of an immunoinflammatory disorder.
Type:
Application
Filed:
September 24, 2003
Publication date:
November 4, 2004
Inventors:
Edward Roydon Jost-Price, Palaniyandi Manivasakam, Brendan Smith, Jason Fong, Benjamin A. Auspitz, M. James Nichols, Curtis Keith, Grant R. Zimmermann, Bradley B. Brasher, Noah Sachs, Todd W. Chappell
Abstract: The uses of celastrol and pristimerin derivatives in the treatment of inflammatory, neurodegenerative and neoplastic diseases are disclosed, including dihydro derivatives of celastrol and pristimerin, such as dihydrocelastrol and dihydropristimerin and their diacetates.
Abstract: Compounds of a histone deacetylase inhibitor. The compounds are capable of simultaneously stimulating epithelium regrowth, inhibiting cutaneous fibroblast proliferation, decreasing collagen deposit, suppressing fibrogenic growth factor and subsiding inflammatory cytokine, and are useful inhibiting the main features of radiation cutaneous syndrome. Results include a decrease in skin swelling, promotion of epithelium healing, and prevention of cutaneous fibrosis, ulceration and necrosis. The present invention provides methods of treating, preventing or ameliorating radiation-induced skin damage by administering a therapeutically effective amount of a histone deacetylase inhibitor.
Abstract: An acidic aqueous hydrogen peroxide solution is provided with improved disinfectant activity. Concentrated solutions preferably contain up to about 8 wt./wt. % H2O2 and as-used concentrations contain about 0.5% wt./wt. % H2O2. The solution also contains from 0.05 to 8.0 wt./wt. % of at least one phosphorous-based acid, e.g. phosphoric acid and/or a phosphonic acid with from 1 to 5 phosphonic acid groups, and from 0.02 to 5 wt./wt. % of at least one anionic surfactant. The surfactant is selected from C8 to C16 alkyl aryl sulfonic acids, sulfonated C12 to C22 carboxylic acids, C8 to C22 alkyl diphenyl oxide sulfonic acids, naphthalene sulfonic acids, C8 to C22 alkyl sulfonic acids, and alkali metal and ammonium salts thereof, and alkali metal C8 to C18 alkyl sulfates, and mixtures thereof. Most preferably the solution has an emulsifier and/or hydrotrope, e.g. an alkylated sulfonated diphenyl oxide salt, an alkyl aryl polyoxyethylene surfactant, and/or a polyoxyethylene surfactant.
Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
Abstract: Two compounds namely ent-pimmarane 8(14),15-diene-19 oic acid (compound 1) and ent-pimmarane 7(8),9(11),15-diene-19 oic acid (compound 2) were isolated from Lavatera cachmeriania, these compounds, in vitro, significantly inhibited the growth of number of human cancer cell lines (CNS : SK-N-MC, Colon : HT-29, Lung : A-549 , Liver: Hep-2, Ovary: OVCAR-5, Prostate: PC-3) representing different organs.
Type:
Application
Filed:
March 28, 2003
Publication date:
September 30, 2004
Applicants:
COUNCIL OF SCIENTIFIC AND INDUSTRIAL, REGIONAL RESEARCH INSTITUTE OF UNANI MEDICINE (Central Council of Research in U.M. New Delhi)
Inventors:
Mohammad Yaseen Dar, Mohammad Yousuf, Mushtaq A. Qurishi, Anees A. Ansari, Shamshad Ahmad, Abdul Sami Shawl, Ajit Kumar Saxena, Gulam Nabi Qazi
Abstract: The present invention relates to methods for regulating the condition of mammalian keratinous tissue wherein the methods each comprise the step of topically applying to the keratinous tissue of a mammal needing such treatment, a safe and effective amount of a skin care composition comprising:
Abstract: This invention relates to topical compositions of an antibacterial benzoquinolizine-2-carboxylic acid, incorporated either as the single therapeutic ingredient in hitherto undescribed pharmaceutical compositions, or as an ingredient in novel combination with at least one agent selected from a retinoid, an antifungal agent, another antibacterial compound and/or a steroid/non-steroid anti-inflammatory agent, to processes for preparation of the compositions, to use of the compositions in preparation of a medicament, and to a method of therapeutic or prophylactic use of such a composition for the treatment of dermal, ophthalmic, otic and nasal infections, with or without attendant inflammation.
Type:
Application
Filed:
December 31, 2003
Publication date:
September 9, 2004
Applicant:
WOCKHARDT LIMITED
Inventors:
Dilip G. Saoji, Rajendra N. Nagori, Milind C. Shukla, Sachin Bhagwat, Shrikant V. Gupte, Mahesh V. Patel, Rasendrakumar Jha, Anil Kukreja, Noel J. De Souza
Abstract: The present invention relates to a feed, a fertilizer, a melanogenesis-inhibitory agent for animals and plants and a blackening/browning-inhibitory composition for animals and plants, each comprising, as an effective component, at least one member selected from the group consisting of pentacyclic triterpenes, physiologically acceptable salts thereof and derivatives thereof, which have an excellent melanogenesis-inhibitory effect.
Abstract: The invention concerns a screening method of a compound modulating the activity of a nuclear RXR-receptor heterodimer, preferably RXR-PPAR. The invention also concerns the compound capable of being selectively hybridised with the gene or a product of the gene coding for the RXR and PPAR subunits of said heterodimer, for preparing a medicine for preventive and/or curative treatment of an infection by the hepatitis C virus, or of fatty liver, of liver inflammation, liver lesions, liver cirrhosis, post-hepatic cancer whether or not associated with a hepatitis C virus infection.
Type:
Application
Filed:
April 26, 2004
Publication date:
September 2, 2004
Inventors:
Pierre Desreumaux, Sebastien Dharancy, Johan Auwerx
Abstract: The present invention relates to methods for preventing the development of epithelial ovarian cancer by administering a Vitamin D compound in an amount capable of increasing apoptosis in non-neoplastic ovarian epithelial cells of the female subject.
Type:
Application
Filed:
February 18, 2004
Publication date:
August 26, 2004
Inventors:
Gustavo C. Rodriguez, Regina Salas Whitaker
Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
Abstract: This invention provides novel antioxidants comprising hydroquinone substituted polyunsaturated fatty acids. Such fatty acids can be obtained from crude kombo butter and are suitable for preventing oxidation of various organic materials. In particular, the invention relates to the use of these fatty acids as antioxidants in the treatment of cancer, the inhibition of proliferation of cells, in lowering levels of cholesterol both in vivo and in vitro and in the treatment of cognitive disorders, including but not limited to Alzheimer's disease.
Abstract: The present invention relates to application of compounds of formula (1) (Gibberellins) and their derivatives for the preparation of a pharmaceutical composition or medicaments for the treatment of diabetes, its complications and associated conditions, including obesity, micro and macro vascular diseases, nephropathy, neuropathy, eye diseases, diabetic ulcerations and the like. The method results the normalization of serum glucose level and other physiological conditions.
Type:
Application
Filed:
February 12, 2004
Publication date:
August 19, 2004
Inventors:
Peter James Jenkins, Minnie Wu, David Shine Wu
Abstract: The invention relates to an alcohol-free liquid concentrate for preserving cosmetic products, household products and technical products, which consists of a carboxylic acid component, a stabilizer component, solvents and optionally customary auxiliaries, additives and/or further active ingredients. Here, the carboxylic acid component comprises at least one salt of benzoic acid, propionic acid, salicylic acid, sorbic acid, 4-hydroxybenzoic acid, dehydroacetic acid and 10-undecylenic acid and optionally one or more of said free acids. The stabilizer component comprises substances which, in particular, have a colour-stabilizing action.
Type:
Application
Filed:
March 29, 2004
Publication date:
August 5, 2004
Inventors:
Wolfgang Beilfuss, Gisela Hahn, Kerstin Hoop, Ralf Gradtke, Klaus Weber
Abstract: Steroid derivatives of this invention interact with nuclear liver X receptor (LXR) and ubiquitous receptor (UR) and can be used to treat a variety of LXR- or UR-mediated disorders.
Type:
Application
Filed:
November 10, 2003
Publication date:
August 5, 2004
Applicant:
Arch Development Corporation, an Illinois corporation
Abstract: The present invention provides use of a compound in the manufacture of a medicament to inhibit 11&bgr;-HSD activity, wherein the compound is selected from glycyrrhetinic acid derivatives, progesterone and progesterone derivatives.
Type:
Application
Filed:
March 17, 2004
Publication date:
July 29, 2004
Inventors:
Barry Victor Lloyd Potter, Atul Purohit, Michael John Reed, Nigel Vicker
Abstract: The object of the present invention is to provide the use of glycyrrhizin and its derivatives for induction of RANTES. The present invention discloses an RANTES induction method and pharmaceutical composition for the same comprising administration of glycyrrhizin and its derivatives in an amount effective for treating or preventing decreases in infection resistance to opportunistic infections occurring in burn patients, AIDS patients, cancer patients, encephalitis patients, individuals having suffered serious injuries or undergone major surgery, or individuals subject to stress.
Abstract: The invention concerns a method for stabilising particle size distribution of a powdery active principle, when the latter is dispersed in a liquid. Said method is characterised in that it consists in dispersing said active principle in a glycol ether or a mixture of glycol ethers. The invention also concerns the uses of said method and, in particular for pharmaceutical compositions and galenic forms comprising a retinoid as active principle, and suited for providing the latter with improved bioavailability (suprabioavailability) after oral administration.
Type:
Application
Filed:
June 10, 2003
Publication date:
July 22, 2004
Inventors:
Rene Gimet, Claude Laruelle, Dominique Toselli
Abstract: The present invention relates to a new cosmetic or pharmaceutical composition charactrized in that it comprises at least on vitamin component chosen from the group consisting of vitamin C and its derivatives, vitamin A (or retinol) and its derivatives, and mixtures of these components, in association with at least one fucose component chosen form the group consisting of fucose, polysacharides and oligosaccharides that contain fucose, sisting of fucose, polysaccharides and oligosaccharides that contain fucose, and mixtures of these components, as well as at least one acceptable excipient. This composition enables one to reduces significantly, by means of a real synergy effect, the toxic effect of the vitamin component and, therefore, to use in the composition contents of the vitamin component higher or equal to the contents of the products that already exist on the market without any risk for the user.
Type:
Application
Filed:
October 20, 2003
Publication date:
July 15, 2004
Inventors:
Robert Ladislas, Alexandre Michel Robert, Catherine Sylvie Robert, Jean-Luc Gesztesi
Abstract: This invention relates to methods and compositions for treating and ameliorating skin conditions including acne, rosacea and wrinkling caused by photodamage or intrinsic aging. More particularly, this invention relates to compositions containing certain natural extracts and natural or synthetic retinoids.
Abstract: The invention concerns a method for the prevention/curing/treatment of diarrhoea in mammals by administering the mammals an effective daily amount of a composition comprising as active component(s) phytosterols and/or pentacyclotriterpenes as present in or derived from Shea oil as well as a method for the preparation of a food or a feed product comprising carbohydrates and proteins wherein the food or feed product has anti-diarrhoea or anti scouring properties by the incorporation of an effective amount of phytosterols and/or pentacyclotriterpenes as present in or derived from Shea oil as active component.
Type:
Application
Filed:
November 21, 2003
Publication date:
July 8, 2004
Applicant:
Loders Croklaan USA LLC
Inventors:
Ulrike Schmid, Wiro Stam, Geoff Collins, Johan Verhaart
Abstract: This invention is drawn to a method of treating hepatitis comprising administering to a subject in need of such treatment a therapeutically effective amount of retinoid such as all-trans retinoic acid. In particular embodiments, the form of hepatitis is Hepatitis A, B, C, D, E and G and the treatment is with liposomal all-trans retinoic acid.
Abstract: The present invention is directed, inter alia, to compositions and methods for treating, healing, or regeneration of ciliated epithelial structures, particularly those of mucosal membranes. In particular, the invention is directed to a method comprising topical administration of vitamin A (including retinoic acid) to ciliated epithelia structures, including, for example, the paranasal sinus mucosa, middle ear epithelium, and tracheal epithelium. In preferred embodiments the inventive methods are used in the context of surgery, and post-surgical healing and regeneration of epithelial and mucosal epithelial structures and cells.
Type:
Application
Filed:
September 8, 2003
Publication date:
June 24, 2004
Inventors:
Mendy S. MacCabee, Peter H. Hwang, Dennis R. Trune
Abstract: The invention relates to the use of C4-C10 acids and/or of at least one of their salts or esters, for preparing a pharmaceutical composition intended to prevent Gram-negative bacterial infections, in particular Salmonella infections.
Abstract: The invention provides compositions and methods that employ compounds that can promote skin cell renewal, wound healing, proliferation of fibroblasts and/or keratinocytes, and production of collagen or fibronectin by fibroblasts. These compositions and methods are useful for rejuvenating the skin and for treating wounds as well as gum-related and skin-related conditions.
Abstract: A capsule system for oral delivery of an active agent having low aqueous solubility generally includes, in combination with the active agent, a vehicle for preventing initial active agent dissolution within the gastrointestinal tract and an emulsifier for promoting self-emulsification of the active agent and vehicle in the gastrointestinal tract. A capsule shell is provided for encapsulating the active agent, vehicle and emulsifier with the shell being formulated to open upon ingestion into the gastrointestinal tract and release the active agent and vehicle.
Abstract: A method is provided of treating an eye with ophthalmologically active compounds, particularly with intra-ocular pressure lowering (IOP) compounds, where a dose of 5-15 microliters is delivered at a standard concentration.
Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
Abstract: The present invention includes compositions and methods for treatment of prostate cancer which involve the use of 12-O-tetradecanoylphorbol-13-acetate combined with a retinoid such as all-trans-retinoic acid or paclitaxol, wherein the drugs are administered together, and further wherein the combined use of these agents results in a synergistic effect on prostate tumor cell growth.
Abstract: Pharmaceutical compositions and methods of treating ulcerating diseases, burns, and related conditions are disclosed. The methods include administering to a host in need of treatment an effective amount of at least one retinoid receptor compound. In addition, the pharmaceutical compositions include at least one retinoid receptor compound in combination with a pharmaceutically acceptable carrier. The retinoid receptor compound can be present in a dosage level effective to treat conditions listed above.
Abstract: Disclosed herein are novel compositions and/or formulations containing minoxidil as an active ingredient in combination with other active agents and/or enhancer agents (e.g., saw palmetto extract and nettle root extract) which increase the hair growth capability of the composition. Also disclosed are methods of using the novel compositions to treat male patterned baldness and to stimulate hair growth on the scalp, including both the apex and frontal regions of the scalp.
Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
Abstract: The invention is a pharmaceutical composition comprising an Lp(a) inhibitor and a statin which inhibits HMG-CoA reductase, said composition being useful for treating vascular diseases.
Type:
Application
Filed:
August 25, 2003
Publication date:
May 13, 2004
Inventors:
Charles Larry Bisgaier, Roger Schofield Newton, Randy Ranjee Ramharack
Abstract: A method of treating a patient with autism to lessen or alleviate associated symptoms of deficient short term memory, inadequate independent problem solving skills, deficient spontaneous verbalizations, utterances of diminished length, infrequent request to interact with family members and friends, insufficient capacity to master complexity of play schemes, and a tendency toward abnormal emotional responses, comprising:
Abstract: The present invention relates to the use of a compound of formula (I), or a pharmaceutically acceptable salt, crystal form, complex, hydrate, or hydrolysable ester thereof, in the preparation of a medicament for treating a patient suffering from leukaemia, cancer or other proliferative disorder. A further embodiment relates to the use a compound of formula (I) in an assay for detecting the phosphorylation state of cellular substrates. The present invention also relates to novel compounds of formula (I), and the chemical synthesis thereof.
Abstract: The present invention relates to a food or beverage comprising at least one member selected from the group consisting of 5-membered ring-containing triterpenes and physiologically acceptable salts or derivatives thereof. The present invention also relates to an orally administered whitening agent comprising, as an effective component, at least one member selected from the group consisting of 5-membered ring-containing triterpenes and physiologically acceptable salts or derivatives thereof.
Abstract: One aspect of the invention relates to anti-viral composition containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients such as at least one analgesic) at least one hydrocarbyl containing compound, and water. Another aspect of the invention relates to a method of treating lesionous symptoms of a viral infection involving applying an effective amount of the zinc containing anti-viral composition to the lesions.
Abstract: This invention relates to a method for treating skin damage, comprising the step of administration of a pharmaceutical or dermatological composition of basic milk factors to the area of the skin of a subject in need of such treatment. The invention further relates to a method for cosmetically treating the aged appearance of skin. The skin damage may be the result of normal biological ageing, environmental factors, dermatological disorders, medical treatments, surgical treatments and/or medical conditions. The aged appearance of skin may be attributed to wrinkles, blemishes, sagging, hyperpigmentation, changes to skin thickness and/or a rough appearance. In a preferred embodiment, the subject in need of such treatment requires the enhancement of the youthful appearance of their skin. The invention further relates to compositions for the treated of these conditions.
Type:
Application
Filed:
March 7, 2003
Publication date:
April 29, 2004
Inventors:
Timothy Edward Rayner, Allison June Cowin, David Andrew Belford
Abstract: A method of treating said musculoskeletal and connective tissue inflammations including osteoarthritis and associated articular and periarticular inflammations, and non-articular Rheumatism including capsulitis, tendonitis, fibrositis, and perarticular inflammations is disclosed. The method includes administering to a patient of a therapeutically effective amount of a composition comprising 13-cis-retinoic acid. Preferably, the treatment method includes administering to a patient of an initial dosage of a composition comprising 13-cis-retinoic acid for an initial treatment period, and thereafter administering a maintenance dosage of the composition.
Abstract: vitamin A, or a derivative of vitamin A having vitamin A like activity is co-administered with inhibitors of the CP450RAI1 and/or of CP450RAI2 enzymes for the purpose of treating diseases and conditions in mammals, including humans, which diseases or conditions are prevented, treated, ameliorated, or the onset of which is delayed by administration of retinoid compounds or by the mammalian organism's naturally occurring retinoic acid.
Type:
Application
Filed:
September 5, 2003
Publication date:
April 22, 2004
Inventors:
Yang-Dar Yuan, Jayasree Vasudevan, Scott Thacher, Roshantha A. Chandraratna
Abstract: Disclosed herein are systemic formulations comprising beta-carotene and derivatives thereof and a solubilizer selected from tetrahydrofuran (THF), polyethylene glycol (PEG), and mixtures thereof. Generally, the formulations are administered to animals in need thereof in therapeutically effective amounts of beta-carotene and derivatives thereof for the purpose intended. The solubilizers greatly enhance the bioavailability of beta-carotene administered systemically. Another embodiment of the present invention is a method for administering beta-carotene and derivatives thereof to an animal in need thereof by administering the formulation of the present invention. Yet another embodiment is a method for treating an animal in need thereof by administering a therapeutically effective amount of the formulation of the present invention.
Abstract: The present invention relates to a new retinyl retinoate, a process for preparing same, a new intermediate which is useful for preparing same, and a cosmetic composition comprising the retinyl retinoate as the active ingredient.
Type:
Application
Filed:
July 16, 2003
Publication date:
April 1, 2004
Inventors:
Young-Soy Roh, Soo-Jong Um, Min-Sook Jeong, Joo-Dong Lee, Hee-Chang Ryoo, Jeong-Kuan Son, Hyo-Jung Kim, Hyuk Kim, Sung-Won Jung, Hye-Sook Han, Si-Ho Park, Seong-Ho Kim